5. Evaluation ..................................................................................................... 237
References ..................................................................................................... 237

INTERNALIZED α-PARTICLE EMITTING RADIONUCLIDES .............................................. 241
1. Exposure Data ................................................................................................ 241
2. Cancer in Humans ........................................................................................ 241
   2.1 Radon ....................................................................................................... 241
   2.2 α-Particle emitters .................................................................................. 250
3. Cancer in Experimental Animals ....................................................................... 264
   3.1 Previous IARC Monograph ................................................................... 264
   3.2 Studies published since the previous IARC Monograph ......................... 265
   3.3 Other studies .......................................................................................... 274
   3.4 Synthesis ............................................................................................... 274
4. Other Relevant Data ......................................................................................... 274
5. Evaluation ..................................................................................................... 274
References ..................................................................................................... 275

INTERNALIZED β-PARTICLE EMITTING RADIONUCLIDES .............................................. 285
1. Exposure Data ................................................................................................ 285
2. Cancer in Humans ........................................................................................ 285
   2.1 Pure β-particle emitters ......................................................................... 285
   2.2 Mixed exposures ..................................................................................... 287
   2.3 Mixed β-particle emitters–radioiodines .................................................... 289
   2.4 Synthesis ............................................................................................... 293
3. Cancer in Experimental Animals ....................................................................... 294
   3.1 Previous evaluation .............................................................................. 294
   3.2 Pure β-particle-emitting radionuclides .................................................... 295
   3.3 Mixed β-particle emitting radionuclides .................................................. 296
   3.4 Synthesis ............................................................................................... 297
4. Other Relevant Data ......................................................................................... 297
5. Evaluation ..................................................................................................... 297
References ..................................................................................................... 298

LIST OF ABBREVIATIONS .......................................................................................... 305

CUMULATIVE CROSS INDEX TO IARC MONOGRAPHS .................................................. 309
NOTE TO THE READER

The term ‘carcinogenic risk’ in the *IARC Monographs* series is taken to mean that an agent is capable of causing cancer. The *Monographs* evaluate cancer hazards, despite the historical presence of the word ‘risks’ in the title.

Inclusion of an agent in the *Monographs* does not imply that it is a carcinogen, only that the published data have been examined. Equally, the fact that an agent has not yet been evaluated in a *Monograph* does not mean that it is not carcinogenic. Similarly, identification of cancer sites with *sufficient evidence* or *limited evidence* in humans should not be viewed as precluding the possibility that an agent may cause cancer at other sites.

The evaluations of carcinogenic risk are made by international working groups of independent scientists and are qualitative in nature. No recommendation is given for regulation or legislation.

Anyone who is aware of published data that may alter the evaluation of the carcinogenic risk of an agent to humans is encouraged to make this information available to the Section of IARC Monographs, International Agency for Research on Cancer, 150 cours Albert Thomas, 69372 Lyon Cedex 08, France, in order that the agent may be considered for re-evaluation by a future Working Group.

Although every effort is made to prepare the *Monographs* as accurately as possible, mistakes may occur. Readers are requested to communicate any errors to the Section of IARC Monographs, so that corrections can be reported in future volumes.